CLIMB BIO, INC. Retained Earnings
CLIMB BIO, INC. (CLYM) had Retained Earnings of -$316.95 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-06
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$316.95M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$303.45M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$289.73M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$272.21M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$316.95M 10-Q · filed 2026-08-06 |
| 2026-03-31 | -$303.45M 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$289.73M 10-Q · filed 2026-08-06 |
| 2025-09-30 | -$272.21M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$259.32M 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$250.66M 10-Q · filed 2025-05-14 |
| 2024-12-31 | -$229.88M 10-K · filed 2026-03-05 |
| 2024-09-30 | -$221.46M 10-Q · filed 2024-11-12 |
| 2024-06-30 | -$212.56M 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$157.68M 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$155.98M 10-K · filed 2025-03-25 |
| 2023-09-30 | -$152.34M 10-Q · filed 2023-11-14 |
| 2023-06-30 | -$148.37M 10-Q · filed 2023-08-10 |
| 2023-03-31 | -$143.15M 10-Q · filed 2023-05-11 |
| 2022-12-31 | -$120.86M 10-K · filed 2024-03-28 |
| 2022-09-30 | -$113.10M 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$103.42M 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$88.82M 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$75.62M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$65.07M 10-Q · filed 2021-11-08 |
| 2021-06-30 | -$55.46M 10-Q · filed 2021-09-13 |
| 2020-12-31 | -$28.14M 10-K · filed 2022-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |